ChAdOx1 nCoV-19 ( DrugBank: ChAdOx1 nCoV-19 )
3 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
46 | 悪性関節リウマチ | 1 |
51 | 全身性強皮症 | 1 |
299 | 嚢胞性線維症 | 1 |
46. 悪性関節リウマチ
臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2021-000880-63-SE (EUCTR) | 11/03/2021 | 23/02/2021 | COVID-19 vaccine in patients with rheumatic diseases: The impact of treatments on the vaccine response protection against infection (COVID19-REUMA) | COVID-19 vaccine in patients with inflammatory rheumatic diseases: The impact of immunomodulating treatments on the antibody response, T cells response and protection against infection (COVID19-REUMA) - COVID19-REUMA | rheumatoid arthritis, SLE, systemic vasculitis, systemic sclerosis, spondylarthritis;Therapeutic area: Body processes [G] - Immune system processes [G12] | Trade Name: Comirnaty Product Name: Comirnaty INN or Proposed INN: COVID-19 mRNA vaccine (nucleoside-modified) Other descriptive name: COVID-19 mRNA vaccine (nucleoside-modified) Trade Name: COVID-19 Vaccine AstraZeneca Product Name: COVID-19 Vaccine AstraZeneca INN or Proposed INN: COVID-19 Vaccine (ChAdOx1-S [recombinant]) Other descriptive name: COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19) Trade Name: COVID-19 Vaccine Moderna Product Name: COVID-19 Vaccine Moderna INN or Proposed INN: COVID-19 mRNA Vaccine (nucleoside modified) Other descriptive name: COVID-19 mRNA vaccine Moderna (CX-024414) | Skåne University Hospital, department of rheumatology in Lud and Malmö | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 868 | Phase 4 | Sweden |
51. 全身性強皮症
臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2021-000880-63-SE (EUCTR) | 11/03/2021 | 23/02/2021 | COVID-19 vaccine in patients with rheumatic diseases: The impact of treatments on the vaccine response protection against infection (COVID19-REUMA) | COVID-19 vaccine in patients with inflammatory rheumatic diseases: The impact of immunomodulating treatments on the antibody response, T cells response and protection against infection (COVID19-REUMA) - COVID19-REUMA | rheumatoid arthritis, SLE, systemic vasculitis, systemic sclerosis, spondylarthritis;Therapeutic area: Body processes [G] - Immune system processes [G12] | Trade Name: Comirnaty Product Name: Comirnaty INN or Proposed INN: COVID-19 mRNA vaccine (nucleoside-modified) Other descriptive name: COVID-19 mRNA vaccine (nucleoside-modified) Trade Name: COVID-19 Vaccine AstraZeneca Product Name: COVID-19 Vaccine AstraZeneca INN or Proposed INN: COVID-19 Vaccine (ChAdOx1-S [recombinant]) Other descriptive name: COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19) Trade Name: COVID-19 Vaccine Moderna Product Name: COVID-19 Vaccine Moderna INN or Proposed INN: COVID-19 mRNA Vaccine (nucleoside modified) Other descriptive name: COVID-19 mRNA vaccine Moderna (CX-024414) | Skåne University Hospital, department of rheumatology in Lud and Malmö | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 868 | Phase 4 | Sweden |
299. 嚢胞性線維症
臨床試験数 : 1,696 / 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2021-003277-55-AT (EUCTR) | 27/07/2021 | COVID-19 Antibody Responses in Cystic Fibrosis: CAR-CF | COVID-19 Antibody Responses in Cystic Fibrosis: CAR-CF - CAR-CF | COVID-19 vaccine Antibody response from natural infection or after vaccination in patients with Cystic Fibrosis (CF) MedDRA version: 20.0;Level: LLT;Classification code 10021433;Term: Immunization;System Organ Class: 100000004865 MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Not possible to specify | Trade Name: Comirnaty concentrate for dispersion for injection Product Name: Comirnaty INN or Proposed INN: Tozinameran Other descriptive name: COVID-19 mRNA vaccine (nucleoside-modified) Trade Name: Vaxzevria suspension for injection COVID-19 Vaccine (ChAdOx1-S Product Name: Vaxzevria INN or Proposed INN: COVID-19 Vaccine (ChAdOx1-S [recombinant]) Other descriptive name: COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19) Trade Name: COVID-19 Vaccine Moderna dispersion for injection Product Name: COVID-19 Vaccine Moderna INN or Proposed INN: Elasomeran Other descriptive name: COVID-19 mRNA vaccine Moderna (CX-024414) Trade Name: COVID-19 Vaccine Janssen suspension for injection Product Name: COVID-19 Vaccine Janssen suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant]) INN or Proposed INN: COVID-19 vaccine (Ad26.COV2-S [recombinant]) Other descriptive name: Ad26.COV2-S.02 | Medical University of Innsbruck, University Clinic for Pediatrics III | NULL | NA | Female: yes Male: yes | 5000 | Phase 4 | United States;European Union;Canada;Ireland;Austria;United Kingdom |